ABSTRACT
Objective To investigate the effects of NovoRapid and biosynthetic human insulin (Novolin-R) on serum cystatin C (Cys C) and homocysteine (HCY) and pregnancy outcome in pregnant women with gestational diabetes mellitus (GDM). Methods A total of 216 cases of GDM pregnant women admitted to our hospital from February 2017 to December 2018 were selected. The patients were divided into observation group (n=112) and control group (n=104) according to the random number table method. Patients in the observation group received NovoRapid treatment, and patients in the control group received Novolin-R treatment. Results The blood glucose compliance time of observation group was significantly shorter than that of control group (P0.05). Conclusion The efficacy of NovoRapid in the treatment of GDM is better than Novolin-R, which could better control blood glucose levels, reduce serum Cys C and HCY levels, and improve pregnancy outcomes. The NovoRapid treatment is worthy of clinical promotion and application.
ABSTRACT
Objective:To compare the efficacy and safety of Novoiaped 30 and NovoMix 30 Flexpen in the therapy of type 2 diabetes mellitus(DM). Methods:A multicenter,randomized,and controlled clinical trial of Novorapid 30R and Novomix 30 Flexpen was performed in XinQiao Hospital in Chongqing China. One hundred and fifty patients with type 2 DM received Novorapid 30R therapy and sixty patients received NovoMix 30 Flexpen for 12 weeks respectively. Results:(1)At the end of 12-week treatment,significant improvements in HbA1C and fasting plasma glucose(FPG) levels were shown in both groups, HbA1C decreased 1.08% and 1.01%,and FPG decreased 2.0mmol/L and 2.2mmol/L,in Novorapid 30R and NovoMix 30 Flexpen group respectively(all P0.05). (2)2hpG decreased 3.79mmol/L and 3.05mmol/L,Novorapid 30R was better than Novomix 30 Flexpen,The difference was statistically significant between two groups(P